Senior Scientific Staff
Andrew Cherniack, PhD
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Jon Goldstein, PhD
Research Scientist II
2014-
PhD, University of Wisconsin - Madison
Phone|Email|LinkedIn
My focus is to understand the biochemical and cellular consequences of genomic alterations in cancer. My goal is to translate these findings into targeted therapeutic candidates.
Research Scientist II
2014-
PhD, University of Wisconsin - Madison
Phone|Email|LinkedIn
My focus is to understand the biochemical and cellular consequences of genomic alterations in cancer. My goal is to translate these findings into targeted therapeutic candidates.
Heidi Greulich, PhD
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Jodi Hirschman, PhD
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Sooncheol (Charlie) Lee, PhD
Research Scientist II
2020-
PhD, Korea Advanced Institute of Science and Technology, South Korea
Phone|Email|LinkedIn
My research focuses on how RNA-binding proteins regulate gene expression post-transcriptionally and their role in the survival of cancer cells. My long-term goal is to induce apoptosis of cancer cells by targeting RNA-binding proteins or post-transcriptional regulation.
Research Scientist II
2020-
PhD, Korea Advanced Institute of Science and Technology, South Korea
Phone|Email|LinkedIn
My research focuses on how RNA-binding proteins regulate gene expression post-transcriptionally and their role in the survival of cancer cells. My long-term goal is to induce apoptosis of cancer cells by targeting RNA-binding proteins or post-transcriptional regulation.
Yvonne Li, PhD, FACMG
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
Gizem Karsli Uzunbas, PhD
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Xiaoyun Wu, PhD
Lead Scientist/Group Leader
2014-
PhD, Wadsworth Center, SUNY Albany and NY State Department of Health
Email|LinkedIn
I am passionate about developing new cancer therapies based on genome-inspired targets. I use traditional and genomic tools to identify potential patient populations and to understand the mechanism of action for promising anti-cancer agents.
Lead Scientist/Group Leader
2014-
PhD, Wadsworth Center, SUNY Albany and NY State Department of Health
Email|LinkedIn
I am passionate about developing new cancer therapies based on genome-inspired targets. I use traditional and genomic tools to identify potential patient populations and to understand the mechanism of action for promising anti-cancer agents.
Junior Scientific Staff
María B. Bacó, B.Sc.
Research Associate III
2017-
B.Sc., University of Puerto Rico - Rio Piedras
Phone|LinkedIn
Creative and self-motivated individual with a passion for understanding the molecular mechanisms that drive disease and how to translate these into therapies that directly impact the treatment of patients.
Research Associate III
2017-
B.Sc., University of Puerto Rico - Rio Piedras
Phone|LinkedIn
Creative and self-motivated individual with a passion for understanding the molecular mechanisms that drive disease and how to translate these into therapies that directly impact the treatment of patients.
Andrew Baker, B.S.
2017-
B.S., Worcester Polytechnic
I am interested in identifying novel therapeutic targets to combat tumorigenesis and metastasis. Currently, I am working to determine the mechanism of action of a first-in-class, small-molecule PDE3A inhibitor that is a promising therapy against tumors expressing PDE3A and SLFN12.
2017-
B.S., Worcester Polytechnic
I am interested in identifying novel therapeutic targets to combat tumorigenesis and metastasis. Currently, I am working to determine the mechanism of action of a first-in-class, small-molecule PDE3A inhibitor that is a promising therapy against tumors expressing PDE3A and SLFN12.
Alyssa Fishbein, B.A.
Research Technician
2019-
B.A., Wellesley College
I work on innate immune signaling, specifically of RNA metabolism, in cancer cells with an ultimate goal of identifying potential novel therapeutic targets.
Research Technician
2019-
B.A., Wellesley College
I work on innate immune signaling, specifically of RNA metabolism, in cancer cells with an ultimate goal of identifying potential novel therapeutic targets.
Stephanie Hoyt, B.A.
Associate Computational Biologist
2020-
B.A., Cornell University
I work on the discovery of new targets for cancer treatments.
Associate Computational Biologist
2020-
B.A., Cornell University
I work on the discovery of new targets for cancer treatments.
Brianna Silverman, B.S.
Research Technician
2019-
B.S., Brandeis University
I assist in experiments focused on uncovering mechanisms of resistance to receptor tyrosine kinase inhibitors in lung cancer. I am currently investigating resistance and sensitivity to EGFR inhibitors.
Research Technician
2019-
B.S., Brandeis University
I assist in experiments focused on uncovering mechanisms of resistance to receptor tyrosine kinase inhibitors in lung cancer. I am currently investigating resistance and sensitivity to EGFR inhibitors.
Liam Spurr, B.S.
Associate Computational Biologist
2018-
B.S., The George Washington University
I, along with the other members of my team, collaborate with physicians around Dana-Farber to design and execute genomic analysis of the Dana-Farber PROFILE clinical targeted sequencing data. I focus on computational and statistical methods development and apply the tools I create to help answer translational research questions.
Associate Computational Biologist
2018-
B.S., The George Washington University
I, along with the other members of my team, collaborate with physicians around Dana-Farber to design and execute genomic analysis of the Dana-Farber PROFILE clinical targeted sequencing data. I focus on computational and statistical methods development and apply the tools I create to help answer translational research questions.
Jackie Watson
Research Technician
2016-
B.A., Amherst College
My work focuses on understanding the molecular and biological consequences of genomic alterations in cancer with the goal of translating these discoveries into effective therapies.
Research Technician
2016-
B.A., Amherst College
My work focuses on understanding the molecular and biological consequences of genomic alterations in cancer with the goal of translating these discoveries into effective therapies.